Over a third of oncology trials disrupted by COVID-19 resume: GlobalData More than one third of oncology trials disrupted by COVID-19 are now back on track (37.8%)- according to the latest report from GlobalData. This marks the largest number of oncology trials resumed since the pandemic disruptions began earlier this year. Oncology trials were seriously impacted by the virus causing many to be paused or suspended.
FDA proposes new rule on reporting requirements to support Right to Try
FDA proposes new rule on reporting requirements to support Right to Try On July 23, the U.S. Food and Drug Administration (FDA) announced a new proposed rule that would require sponsors and manufacturers who provide an ‘‘eligible investigational drug’’ under the Right to Try Act to submit an annual summary of such use to FDA. The Right to Try Act (RTT), or the Trickett Wendler, Frank Mongiello,
EU cancer estimates for 2020 reveal 2.7 million new cases
EU cancer estimates for 2020 reveal 2.7 million new cases The European Joint Research Council (JRC) released its 2020 burden of cancer estimates on 22 July, 2020. The report revealed The cancer burden is estimated to have risen to 2.7 million new cases (all types, excluding non-melanoma skin cancer) and 1.3 million deaths in 2020. Female breast cancer remains the most commonly diagnosed. Key findings:

Schedule a meeting

We are excited to connect with you, understand your goals, and explore how we can support your needs.

Contact us